基于微阵列化学发光免疫分析系统的血清肿瘤标记物CA72-4参考区间建立
Establishment of Reference Interval for the Serum Tumour Marker CA72-4 Measured by the Microarray Chemiluminescence Immunoassay System
摘要: 目的:目前,多种血清肿瘤标记物已应用于癌症的诊断、治疗和预后监测。因此,建立合适的肿瘤标记物的参考区间(RI)对于临床医生制定正确的治疗方案非常重要。本研究旨在通过实验室新设立的微阵列化学发光免疫分析系统(MCI)来建立血清糖类抗原72-4 (CA72-4)的参考区间。方法:根据CLSI EP28-A3,选择了相应的统计学分析方法,并基于分析结果采用间接法确定参考区间。研究共选用5937名健康参考个体,通过MCI系统测定的CA72-4血清水平来确定参考区间。这四个研究项目的所有测试数据都呈偏态分布。首先,性别和年龄是影响检测价值水平的两个重要因素。其次,按性别和年龄对数据进行分组,使用非参数排序法建立每个组的参考区间。结果:血清CA72-4水平总体呈偏态分布,不同性别、年龄组的血清CA72-4水平无统计学意义。因此,可以通过非参数排序法,按照95%置信区间计算出健康个体的CA72-4参考区间是0~13.34 U/mL。结论:新建立的参考区间更适合国内研发的MCI系统,对于临床医学诊断和治疗管理决策更有价值。
Abstract: Purpose: A variety of serum biomarkers have been applied to the diagnosis, treatment and prog-nosis monitoring of cancers. So, appropriate reference intervals (RI) of tumour markers are im-portant for clinicians to make a right clinical practice. In this study, we aimed to establish the RIs for the carbohydrate antigen 72-4 (CA72-4) measured by the newly developed microarray chemiluminescence immunoassay (MCI) system in our laboratory. Methods: According to CLSI EP28-A3, the appropriate statistical analysis method was selected and the RIs were determined using the indirect method based on the analysis results. A total of 5937 healthy reference indi-viduals were selected and their serum level of CA72-4 measured by MCI system were analysed in this study to establish the reference interval. All the test data of the four research projects showed a skewness distribution. Firstly, gender and age are two important factors influencing the level of detection value. Next, the data were grouped by gender and age, and the non-parametric percentile method was used to establish the RIs of each group. Results: The results showed the distribution for serum CA72-4 level was skewed and the serum CA72-4 levels among gender and age subgroups were no statistically significant. Thus, the RI of CA72-4 for healthy individuals was 0~13.34 U/mL defined by nonparametric 95th percentile interval, which also had passed through the RI verification. Conclusion: The novel established RI was more appropriate for the domestic developed MCI system, which was of great value in medical diagnosis and therapeutic management decision.
文章引用:刘昕翌, 周倩, 杨渝伟, 吴碧涛, 余琳. 基于微阵列化学发光免疫分析系统的血清肿瘤标记物CA72-4参考区间建立[J]. 临床医学进展, 2022, 12(4): 3278-3285. https://doi.org/10.12677/ACM.2022.124473

参考文献

[1] Siegel, R.L., Miller, K.D. and Jemal, A. (2019) Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 7-34. [Google Scholar] [CrossRef] [PubMed]
[2] Thrift, A.P. and El-Serag, H.B. (2020) Burden of Gastric Cancer. Clinical Gastroenterology and Hepatology, 18, 534-542. [Google Scholar] [CrossRef] [PubMed]
[3] Sitarz, R., Skierucha, M., Mielko, J., Offerhaus, G.J.A., Maciejewski, R. and Polkowski, W.P. (2018) Gastric Cancer: Epidemiology, Prevention, Classification, and Treatment. Cancer Management and Research, 10, 239-248. [Google Scholar] [CrossRef
[4] Machlowska, J., Puculek, M., Sitarz, M., Terlecki, P., Maciejewski, R. and Sitarz, R. (2019) State of the Art for Gastric Signet Ring Cell Carcinoma: From Classification, Prognosis, and Genomic Characteristics to Specified Treatments. Cancer Management and Research, 11, 2151-2161. [Google Scholar] [CrossRef
[5] Matsuoka, T. and Yashiro, M. (2018) Biomarkers of Gastric Cancer: Current Topics and Future Perspective. World Journal of Gastroenterology, 24, 2818-2832. [Google Scholar] [CrossRef] [PubMed]
[6] Wu, D., Zhang, P., Ma, J., Xu, J., Yang, L., Xu, W., et al. (2019) Serum Biomarker Panels for the Diagnosis of Gastric Cancer. Cancer Medicine, 8, 1576-1583. [Google Scholar] [CrossRef] [PubMed]
[7] Shigeyasu, K., Toden, S., Zumwalt, T.J., Okugawa, Y. and Goel, A. (2017) Emerging Role of MicroRNAs as Liquid Biopsy Biomarkers in Gastrointestinal Cancers. Clinical Cancer Research, 23, 2391-2399. [Google Scholar] [CrossRef
[8] Zheng, T.H., Zhao, J.L. and Guleng, B. (2015) Advances in Molecular Biomarkers for Gastric Cancer. Critical Reviews in Eukaryotic Gene Expression, 25, 299-305. [Google Scholar] [CrossRef
[9] Konforte, D. and Diamandis, E.P. (2013) Is Early Detection of Cancer with Circulating Biomarkers Feasible? Clinical Chemistry, 59, 35-37. [Google Scholar] [CrossRef] [PubMed]
[10] Correa, P. (2010) Serum Pepsinogens in Gastric Cancer Screening. Digestive Diseases and Sciences, 55, 2123-2125. [Google Scholar] [CrossRef] [PubMed]
[11] Shimada, H., Noie, T., Ohashi, M., Oba, K. and Takahashi, Y. (2014) Clinical Significance of Serum Tumor Markers for Gastric Cancer: A Systematic Review of Literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer, 17, 26-33. [Google Scholar] [CrossRef] [PubMed]
[12] Jing, J.X., Xu, X.Q., Du, L.L., Tian, B.G., Sun, T., Zhao, X.W., et al. (2013) Clinical Assessment and Prognostic Evaluation of Tumor Markers in Patients with Gastric Cancer. The International Journal of Biological Markers, 28, 192-200. [Google Scholar] [CrossRef
[13] Sun, Z. and Zhang, N. (2014) Clinical Evaluation of CEA, CA19-9, CA72-4 and CA125 in Gastric Cancer Patients with Neoadjuvant Chemotherapy. World Journal of Surgical Oncology, 12, 397-400. [Google Scholar] [CrossRef] [PubMed]
[14] Mariampillai, A.I., Cruz, J.P.D., Suh, J., Sivapiragasam, A., Nevins, K. and Hindenburg, A.A. (2017) Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries. Anticancer Research, 37, 3649-3656.
[15] Johnson, V.G., Schlom, J., Paterson, A.J., Bennett, J., Magnani, J.L. and Colcher, D. (1986) Analysis of a Human Tumor-Associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3. Cancer Research, 46, 850-857.
[16] Zhao, B., Zhang, M., Liu, D., Ren, Y., Xie, J., Liang, Y., et al. (2018) Establishment of Reference Interval for the Tumour Marker Serum CYFRA 21-1 in Healthy Chinese Han Ethnic Adults. Scandinavian Journal of Clinical and Laboratory Investigation, 78, 171-174. [Google Scholar] [CrossRef] [PubMed]
[17] Yang, J., Tang, A., Ma, J., Sun, X. and Ming, L. (2019) The Reference Intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1. Scandinavian Journal of Clinical and Laboratory Investigation, 79, 71-74. [Google Scholar] [CrossRef] [PubMed]
[18] Liang, Y., Wang, W., Fang, C., Raj, S.S., Hu, W.M., Li, Q.W., et al. (2016) Clinical Significance and Diagnostic Value of Serum CEA, CA19-9 and CA72-4 in Patients with Gastric Cancer. Oncotarget, 7, 49565-49573. [Google Scholar] [CrossRef] [PubMed]
[19] Chen, C., Chen, Q., Zhao, Q., Liu, M. and Guo, J. (2017) Value of Combined Detection of Serum CEA, CA72-4, CA19-9, CA15-3 and CA12-5 in the Diagnosis of Gastric Cancer. Annals of Clinical & Laboratory Science, 47, 260-263.
[20] Yu, J., Zhang, S. and Zhao, B. (2016) Differences and Correlation of Serum CEA, CA19-9 and CA72-4 in Gastric Cancer. Molecular and Clinical Oncology, 4, 441-449. [Google Scholar] [CrossRef] [PubMed]